Base de dados : MEDLINE
Pesquisa : D27.505.954.444.400 [Categoria DeCS]
Referências encontradas : 2486 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 249 ir para página                         

  1 / 2486 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29186249
[Au] Autor:Sumita JM; Leonardi GR; Bagatin E
[Ad] Endereço:Dermatology Department of the Paulista Medical School - Universidade Federal de São Paulo (EPM - UNIFESP) - São Paulo (SP), Brazil.
[Ti] Título:Tretinoin peel: a critical view.
[So] Source:An Bras Dermatol;92(3):363-366, 2017 May-Jun.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The tretinoin peel, also known as retinoic acid peel, is a superficial peeling often performed in dermatological clinics in Brazil. The first study on this was published in 2001, by Cuce et al., as a treatment option for melasma. Since then, other studies have reported its applicability with reasonable methodology, although without a consistent scientific background and consensus. Topical tretinoin is used for the treatment of various dermatoses such as acne, melasma, scars, skin aging and non-melanoma skin cancer. The identification of retinoids cellular receptors was reported in 1987, but a direct cause-effect relation has not been established. This article reviews studies evaluating the use of topical tretinoin as agent for superficial chemical peel. Most of them have shown benefits in the treatment of melasma and skin aging. A better quality methodology in the study design, considering indication and intervention is indispensable regarding concentration, vehicle and treatment regimen (interval and number of applications). Additionally, more controlled and randomized studies comparing the treatment with tretinoin cream versus its use as a peeling agent, mainly for melasma and photoaging, are necessary.
[Mh] Termos MeSH primário: Abrasão Química/métodos
Ceratolíticos/administração & dosagem
Envelhecimento da Pele/efeitos dos fármacos
Dermatopatias/tratamento farmacológico
Tretinoína/administração & dosagem
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Keratolytic Agents); 5688UTC01R (Tretinoin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE


  2 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28715585
[Au] Autor:Joubert R; Daniel E; Bonnin N; Comptour A; Gross C; Belville C; Chiambaretta F; Blanchon L; Sapin V
[Ad] Endereço:Centre Hospitalo-Universitaire, Clermont-Ferrand, Ophthalmology Department, Clermont-Ferrand, France 2Translational Approach to Epithelial Injury and Repair Team, Université Clermont Auvergne, Centre National de Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Génét
[Ti] Título:Retinoic Acid Engineered Amniotic Membrane Used as Graft or Homogenate: Positive Effects on Corneal Alkali Burns.
[So] Source:Invest Ophthalmol Vis Sci;58(9):3513-3518, 2017 Jul 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: Alkali burns are the most common, severe chemical ocular injuries, their functional prognosis depending on corneal wound healing efficiency. The purpose of our study was to compare the benefits of amniotic membrane (AM) grafts and homogenates for wound healing in the presence or absence of previous all-trans retinoic acid (atRA) treatment. Methods: Fifty male CD1 mice with reproducible corneal chemical burn were divided into five groups, as follows: group 1 was treated with saline solution; groups 2 and 3 received untreated AM grafts or grafts treated with atRA, respectively; and groups 4 and 5 received untreated AM homogenates or homogenates treated with atRA, respectively. After 7 days of treatment, ulcer area and depth were measured, and vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) were quantified. Results: AM induction by atRA was confirmed via quantification of retinoic acid receptor ß (RARß), a well-established retinoic acid-induced gene. Significant improvements of corneal wound healing in terms of ulcer area and depth were obtained with both strategies. No major differences were found between the efficiency of AM homogenates and grafts. This positive action was increased when AM was pretreated with atRA. Furthermore, AM induced a decrease in VEGF and MMP-9 levels during the wound healing process. The atRA treatment led to an even greater decrease in the expression of both proteins. Conclusions: Amnion homogenate is as effective as AM grafts in promoting corneal wound healing in a mouse model. A higher positive effect was obtained with atRA treatment.
[Mh] Termos MeSH primário: Âmnio/efeitos dos fármacos
Âmnio/transplante
Queimaduras Químicas/cirurgia
Úlcera da Córnea/cirurgia
Queimaduras Oculares/induzido quimicamente
Ceratolíticos/farmacologia
Tretinoína/farmacologia
[Mh] Termos MeSH secundário: Álcalis
Animais
Queimaduras Químicas/metabolismo
Úlcera da Córnea/metabolismo
Modelos Animais de Doenças
Técnica Indireta de Fluorescência para Anticorpo
Seres Humanos
Masculino
Metaloproteinase 9 da Matriz/metabolismo
Camundongos
Engenharia Tecidual
Transplantes
Fator A de Crescimento do Endotélio Vascular/metabolismo
Cicatrização/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkalies); 0 (Keratolytic Agents); 0 (Vascular Endothelial Growth Factor A); 0 (vascular endothelial growth factor A, mouse); 5688UTC01R (Tretinoin); EC 3.4.24.35 (Matrix Metalloproteinase 9); EC 3.4.24.35 (Mmp9 protein, mouse)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170728
[Lr] Data última revisão:
170728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-21810


  3 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28647025
[Au] Autor:Melnik BC
[Ad] Endereço:Department of Dermatology, Environmental Medicine, Health Theory, Faculty of Human Sciences, University of Osnabrück, Osnabrück, Germany. Electronic address: melnik@t-online.de.
[Ti] Título:Olumacostat Glasaretil, a Promising Topical Sebum-Suppressing Agent that Affects All Major Pathogenic Factors of Acne Vulgaris.
[So] Source:J Invest Dermatol;137(7):1405-1408, 2017 Jul.
[Is] ISSN:1523-1747
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hunt et al. show that olumacostat glasaretil, an inhibitor of acetyl coenzyme A carboxylase, reduces saturated and monounsaturated fatty acyl chains in sebaceous lipids. Topical olumacostat glasaretil application decreases hamster ear sebaceous gland size and shows efficacy in treating patients with acne vulgaris. Olumacostat glasaretil-mediated sebum suppression may reduce Propionibacterium acnes growth and biofilm formation, comedogenesis, and inflammation.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Sebo/efeitos dos fármacos
Tretinoína/administração & dosagem
[Mh] Termos MeSH secundário: Acne Vulgar/metabolismo
Administração Cutânea
Seres Humanos
Ceratolíticos/administração & dosagem
Sebo/secreção
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Keratolytic Agents); 5688UTC01R (Tretinoin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170626
[St] Status:MEDLINE


  4 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28614013
[Au] Autor:Ijaz N; Fitzgerald D
[Ad] Endereço:Specialty Doctor in Dermatology, Dermatology Department, Salford Royal Hospital, Manchester M6 8HD.
[Ti] Título:Seborrhoeic dermatitis.
[So] Source:Br J Hosp Med (Lond);78(6):C88-C91, 2017 Jun 02.
[Is] ISSN:1750-8460
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Corticosteroides/uso terapêutico
Antifúngicos/uso terapêutico
Dermatite Seborreica/terapia
Inibidores Enzimáticos/uso terapêutico
Ceratolíticos/uso terapêutico
Fototerapia
[Mh] Termos MeSH secundário: Administração Cutânea
Lesões Encefálicas Traumáticas/epidemiologia
Inibidores de Calcineurina
Dermatite Seborreica/epidemiologia
Dermatite Seborreica/imunologia
Dermatomicoses/epidemiologia
Dieta
Dermatoses Faciais
Seres Humanos
Imidazóis/uso terapêutico
Malassezia
Compostos Organometálicos/uso terapêutico
Doença de Parkinson/epidemiologia
Piridinas/uso terapêutico
Fatores de Risco
Dermatoses do Couro Cabeludo
Compostos de Selênio/uso terapêutico
Traumatismos da Medula Espinal/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Antifungal Agents); 0 (Calcineurin Inhibitors); 0 (Enzyme Inhibitors); 0 (Imidazoles); 0 (Keratolytic Agents); 0 (Organometallic Compounds); 0 (Pyridines); 0 (Selenium Compounds); 7GBN705NH1 (imidazole); R953O2RHZ5 (pyrithione zinc); Z69D9E381Q (selenium disulfide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.12968/hmed.2017.78.6.C88


  5 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28538881
[Au] Autor:Al-Talib H; Al-Khateeb A; Hameed A; Murugaiah C
[Ad] Endereço:Laboratory Medical Science Cluster, Faculty of Medicine, Universiti Teknologi MARA (UiTM) - Sungai Buloh, Malaysia.
[Ti] Título:Efficacy and safety of superficial chemical peeling in treatment of active acne vulgaris.
[So] Source:An Bras Dermatol;92(2):212-216, 2017 Mar-Apr.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Acne vulgaris is an extremely common condition affecting the pilosebaceous unit of the skin and characterized by presence of comedones, papules, pustules, nodules, cysts, which might result in permanent scars. Acne vulgaris commonly involve adolescents and young age groups. Active acne vulgaris is usually associated with several complications like hyper or hypopigmentation, scar formation and skin disfigurement. Previous studies have targeted the efficiency and safety of local and systemic agents in the treatment of active acne vulgaris. Superficial chemical peeling is a skin-wounding procedure which might cause some potentially undesirable adverse events. This study was conducted to review the efficacy and safety of superficial chemical peeling in the treatment of active acne vulgaris. It is a structured review of an earlier seven articles meeting the inclusion and exclusion criteria. The clinical assessments were based on pretreatment and post-treatment comparisons and the role of superficial chemical peeling in reduction of papules, pustules and comedones in active acne vulgaris. This study showed that almost all patients tolerated well the chemical peeling procedures despite a mild discomfort, burning, irritation and erythema have been reported; also the incidence of major adverse events was very low and easily manageable. In conclusion, chemical peeling with glycolic acid is a well-tolerated and safe treatment modality in active acne vulgaris while salicylic acid peels is a more convenient for treatment of darker skin patients and it showed significant and earlier improvement than glycolic acid.
[Mh] Termos MeSH primário: Acne Vulgar/terapia
Abrasão Química/métodos
Glicolatos/uso terapêutico
Ceratolíticos/uso terapêutico
Ácido Salicílico/uso terapêutico
[Mh] Termos MeSH secundário: Abrasão Química/efeitos adversos
Eritema/etiologia
Seres Humanos
Salicilatos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Glycolates); 0 (Keratolytic Agents); 0 (Salicylates); 0WT12SX38S (glycolic acid); O414PZ4LPZ (Salicylic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE


  6 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28488421
[Au] Autor:Abd Eldaim MA; Matsuoka S; Okamatsu-Ogura Y; Kamikawa A; Ahmed MM; Terao A; Nakajima KI; Kimura K
[Ad] Endereço:Laboratories of Biochemistry, Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan.
[Ti] Título:Retinoic acid modulates lipid accumulation glucose concentration dependently through inverse regulation of SREBP-1 expression in 3T3L1 adipocytes.
[So] Source:Genes Cells;22(6):568-582, 2017 Jun.
[Is] ISSN:1365-2443
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:It is well known that retinoic acid (RA) suppresses adipogenesis, although there are some contradicting reports. In this study, we examined the effect of extracellular glucose on RA-induced suppression of adipogenesis in 3T3L1 cell culture. When the cells were cultured in normal glucose medium (NG), the addition of RA suppressed lipid accumulation. However, when cultured in high glucose medium (HG), addition of RA to the cells enhanced lipid accumulation. These changes were accompanied by parallel alterations in fatty acid synthase (FAS) and sterol regulatory element-binding protein (SREBP)-1 gene expression. Transfection of SREBP-1 siRNA suppressed RA-induced enhancement of lipid accumulation and FAS expression in the cells cultured with HG. Transfection of the nuclear form of SREBP-1a cDNA into the cells cultured with NG inhibited RA-induced suppression of lipid accumulation and FAS expression. Moreover, RA- and HG-induced SREBP-1a expression occurred at the early phase of adipogenesis and was dependent on glucocorticoid to induce liver X receptor (LXR) ß, peroxisomal proliferator-activated receptor (PPAR) γ and retinoid X receptor (RXR), the key nuclear factors influencing the SREBP-1a gene expression. These results suggest that RA suppresses and enhances lipid accumulation through extracellular glucose concentration-dependent modulation of SREBP-1 expression.
[Mh] Termos MeSH primário: Adipócitos/metabolismo
Regulação da Expressão Gênica/efeitos dos fármacos
Glucose/metabolismo
Metabolismo dos Lipídeos/efeitos dos fármacos
Proteína de Ligação a Elemento Regulador de Esterol 1/metabolismo
Tretinoína/farmacologia
[Mh] Termos MeSH secundário: Células 3T3-L1
Adipócitos/citologia
Adipócitos/efeitos dos fármacos
Animais
Ácido Graxo Sintases/genética
Ácido Graxo Sintases/metabolismo
Seres Humanos
Ceratolíticos/farmacologia
Camundongos
Proteína de Ligação a Elemento Regulador de Esterol 1/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Keratolytic Agents); 0 (SREBF1 protein, human); 0 (Sterol Regulatory Element Binding Protein 1); 5688UTC01R (Tretinoin); EC 2.3.1.85 (Fatty Acid Synthases); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170511
[St] Status:MEDLINE
[do] DOI:10.1111/gtc.12498


  7 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28400341
[Au] Autor:Yu C; Fan X; Li Z; Liu X; Wang G
[Ad] Endereço:Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
[Ti] Título:Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
[So] Source:Eur J Dermatol;27(2):150-154, 2017 Apr 01.
[Is] ISSN:1952-4013
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Although acitretin has been widely used for the treatment of psoriasis, additional safer and more effective approaches, including traditional Chinese medicine, are needed. To investigate the efficacy and safety of total glucosides of paeony (TGP) combined with acitretin in the treatment of moderate-to-severe plaque psoriasis. A randomised, double-blind, placebo-controlled, multi-centre clinical study was conducted. In total, 108 patients with moderate-to-severe plaque psoriasis were randomly assigned to treatment with "TGP plus acitretin" (group A) or "placebo plus acitretin" (group B) for 12 weeks. After 12 weeks of therapy, the percentage of patients achieving a 50% reduction in Psoriasis Area and Severity Index was 90% in group A and 70.5% in group B (p<0.05). The rate of serum alanine aminotransferase elevation was 6.25% in group A and 20.4% in group B (p<0.05). TGP is conducive to enhancing anti-psoriatic efficacy and reducing liver damage due to acitretin. TGP combined with acitretin is a safe and effective treatment approach for moderate-to-severe plaque psoriasis.
[Mh] Termos MeSH primário: Acitretina/uso terapêutico
Glucosídeos/uso terapêutico
Ceratolíticos/uso terapêutico
Paeonia/química
Fitoterapia
Extratos Vegetais/uso terapêutico
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Acitretina/efeitos adversos
Adulto
Alanina Transaminase/sangue
Doença Hepática Induzida por Substâncias e Drogas/etiologia
Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Glucosídeos/efeitos adversos
Seres Humanos
Ceratolíticos/efeitos adversos
Masculino
Meia-Idade
Extratos Vegetais/efeitos adversos
Raízes de Plantas
Fatores de Proteção
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucosides); 0 (Keratolytic Agents); 0 (Plant Extracts); EC 2.6.1.2 (Alanine Transaminase); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170413
[St] Status:MEDLINE
[do] DOI:10.1684/ejd.2016.2946


  8 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28329527
[Au] Autor:Joshipura D; Goldminz A; Greb J; Gottlieb A
[Ad] Endereço:Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. djoshipura@tuftsmedicalcenter.org.
[Ti] Título:Acitretin for the treatment of recalcitrant plantar warts.
[So] Source:Dermatol Online J;23(3), 2017 Mar 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Plantar warts caused by human papilloma virus (HPV)may be challenging to treat when conventionalmodalities fail. We report a case of severely recalcitrantplantar warts, successfully treated with oral acitretinand topical 40% urea cream.
[Mh] Termos MeSH primário: Acitretina/uso terapêutico
Dermatoses do Pé/tratamento farmacológico
Ceratolíticos/uso terapêutico
Ureia/uso terapêutico
Verrugas/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Administração Oral
Adulto
Doenças do Pé/tratamento farmacológico
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Keratolytic Agents); 8W8T17847W (Urea); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE


  9 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28329514
[Au] Autor:Asemota E; Markova A; Ho J; Lichtman MK
[Ti] Título:Disseminated punctate keratoderma: a rare case report and review of the literature.
[So] Source:Dermatol Online J;23(3), 2017 Mar 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We report a rare case of a 53-year-old womanpresenting with diffuse, late-onset disseminatedhyperkeratotic papules. Biopsy showed massivehyperkeratosis overlying a crateriform epidermaldepression and hypergranulosis with mild epidermalhyperplasia. There was no parakeratosis, cornoidlamella, or dyskeratosis. Based on the clinical findingsand histopathological features, a diagnosis ofdisseminated punctate keratoderma was made. Thisis a rare subtype of palmoplantar keratoderma, whichhas a putative increased risk of malignancy. This casereport emphasizes the importance of identifyingthe clinical and histological presentation of this rarecondition; referral of the patient for age-appropriatemalignancy screening is appropriate. We also presenta concise review of treatment options.
[Mh] Termos MeSH primário: Ceratodermia Palmar e Plantar/diagnóstico
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Feminino
Seres Humanos
Ceratodermia Palmar e Plantar/classificação
Ceratodermia Palmar e Plantar/patologia
Ceratodermia Palmar e Plantar/terapia
Ceratolíticos/uso terapêutico
Meia-Idade
Terapia PUVA
Retinoides/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Keratolytic Agents); 0 (Retinoids)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE


  10 / 2486 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28328264
[Au] Autor:Croney S
[Ad] Endereço:Clinical Nurse Lead Dermatology, Medway NHS Foundation Trust.
[Ti] Título:Management of patients with psoriasis.
[So] Source:Br J Nurs;26(5):260-262, 2017 Mar 09.
[Is] ISSN:0966-0461
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Stacey Croney, Clinical Nurse Lead Dermatology, Medway NHS Foundation Trust, Kent discusses the care of patients with psoriasis, including the latest drug treatments.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Emolientes/uso terapêutico
Imunossupressores/uso terapêutico
Fototerapia
Psoríase/terapia
[Mh] Termos MeSH secundário: Acitretina/uso terapêutico
Administração Cutânea
Betametasona/uso terapêutico
Calcitriol/análogos & derivados
Calcitriol/uso terapêutico
Ciclosporina/uso terapêutico
Gerenciamento Clínico
Seres Humanos
Ceratolíticos/uso terapêutico
Metotrexato/uso terapêutico
Psoríase/diagnóstico
Psoríase/patologia
Talidomida/análogos & derivados
Talidomida/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Dermatologic Agents); 0 (Emollients); 0 (Immunosuppressive Agents); 0 (Keratolytic Agents); 143NQ3779B (calcipotriene); 4Z8R6ORS6L (Thalidomide); 83HN0GTJ6D (Cyclosporine); 9842X06Q6M (Betamethasone); FXC9231JVH (Calcitriol); LCH760E9T7 (Acitretin); UP7QBP99PN (apremilast); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170615
[Lr] Data última revisão:
170615
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.12968/bjon.2017.26.5.260



página 1 de 249 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde